AstraZeneca plc (AZN) Price Target Cut to GBX 4,600 by Analysts at JPMorgan Chase & Co.
AstraZeneca plc (LON:AZN) had its price objective lowered by JPMorgan Chase & Co. from GBX 4,900 ($60.79) to GBX 4,600 ($57.06) in a research note published on Monday morning. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the company. HSBC set a GBX 4,815 ($59.73) price target on AstraZeneca plc and gave the company a neutral rating in a research report on Tuesday, August 2nd. Beaufort Securities reaffirmed a hold rating on shares of AstraZeneca plc in a research report on Wednesday, August 10th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.62) target price on shares of AstraZeneca plc and gave the company a sell rating in a research note on Wednesday, August 10th. Jefferies Group increased their target price on shares of AstraZeneca plc from GBX 4,800 ($59.55) to GBX 5,050 ($62.65) and gave the company a hold rating in a research note on Thursday, August 4th. Finally, Berenberg Bank reiterated a buy rating and issued a GBX 5,550 ($68.85) target price on shares of AstraZeneca plc in a research note on Thursday, September 8th. Four research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Hold and an average target price of GBX 4,958.40 ($61.51).
AstraZeneca plc (LON:AZN) opened at 4243.50 on Monday. The company’s market capitalization is GBX 53.68 billion. The company has a 50-day moving average price of GBX 4,592.74 and a 200-day moving average price of GBX 4,592.37. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.